Archives

Notice to Attend the Extraordinary General Meeting in Scandinavian Real Heart AB

Press Release November 8, 2023

The shareholders in Scandinavian Real Heart AB, reg. no. 556729-5588 (the "Company"), are hereby invited to the Annual General Meeting on Friday, 24 November 2023 at 10.00 at Best Western Plus Hotel Plaza, Kopparbergsvägen 10, 722 13 Västerås. Registration for the Meeting begins at 09:30.

Right to participate in the Meeting, etc.

Shareholders who wish to participate in the Meeting shall

  • be recorded in the share register kept by Euroclear Sweden AB no later than Thursday, 16 November 2023, and
  • notify the Company their intention to participate no later than Monday, 20 November 2023 by post to Scandinavian Real Heart AB, Kopparbergsvägen 6, 722 13 Västerås, by phone +46 (0)70-643 88 61 or by e-mail jonas.bark@realheart.se.The notification shall state full name, personal identification number/company registration number, shareholding, address, daytime telephone number and, if applicable, information about proxies or assistants (maximum two).

To be entitled to participate in the Meeting, shareholders whose shares are held in the name of a nominee must, in addition to providing notification of their participation in the Meeting, re-register the shares in their own name so that the shareholders are registered in the share register on the record date on Thursday, 16 November 2023. This re-registration may be temporary (so-called "voting right registration") and is carried out through the nominee according to their procedures at a time predetermined by the nominee. Voting rights registration that has been completed by the nominee no later than Monday, 20 November 2023, are considered when preparing the share register.

Proxies etc.

If a Shareholders shall be represented by proxy, the proxy shall bring a written, dated and by the shareholder signed, power of attorney to the Meeting. The power of attorney may not be older than one year unless indicated that it is valid for a longer period, not exceeding five years. If the proxy is issued by a legal person, the proxy shall bring a current copy of the registration certificate and similar papers of authorisation. In order to facilitate entry to the Meeting, a copy of the power of attorney and other authorisation documents should be attached to the notification to the Meeting. Proxy forms will be available on the Company's website www.realheart.se and will be sent by post to shareholders who contact the Company and state their address.

Processing of personal data

For information on how personal data is processed in connection with the Meeting, please refer to the privacy policy available on Euroclear Sweden AB's website: https://www.euroclear.com/dam/ESw/Legal/Integritypolicy-bolagsstammor-svenska.pdf.

Proposal for agenda

1.
Election of Chairman of the Meeting

2.
Election of one or two persons to verify the minutes

3.
Preparation and approval of the voting list

4.
Approval of the agenda

5.
Determination as to whether the meeting has been duly convened

6.
Determination of number of Board members

7.
Election of Board members

8.
Determination of fees for Board members

9.
Closing of meeting

The Nomination Committee's proposals

Item 1 – Election of Chairman of the Meeting

The Nomination Committee consists, until the Annual General Meeting 2024, of Kim Norström and Azad Najar as decided by the Annual General Meeting 2023. The Nomination Committee proposes that Christer Norström, or the person appointed by the Nomination Committee if he is prevented from attending, is appointed as Chairman of the Extraordinary General Meeting.

Item 6 – Determination of number of Board members

The Nomination Committee proposes that the Board of Directors should consist of eight

ordinary Board members without deputies.

Item 7 -Election of Board members

The Nomination Committee proposes, for the period until the end of the next Annual General Meeting, that the current Board of Directors be supplemented with the following new members: Magnus Öhman, Stuart McConchie and Giovanni Lauricella. The board of directors otherwise consists of the members Christer Norström, also chairman of the board, Azad Najar, Ulf Grape, Oliver Voigt and Solveig Bergström as board members.

Magnus Öhman

Born: 1961
Education: MSc in Mechanical Engineering
Board of Director assignments: Magnus is currently Chairman of the board of Neosense Technologies, a Swedish medtech start-up company that develops invasive sensor based products where the first product significantly improves continuous oxygen monitoring for neonatal children to improve survival rate and Quality of Life. He has been a board member at Stockholms Tekniska Institut, an engineering school founded in 1924.

Experience: Magnus has over 30 years of experience from medtech including R&D leadership in both site and global responsibilities and as Managing Director for the St Jude Medical CRM subsidiary with  R&D, manufacturing and distribution operations with over 600 employees and a revenue of 5.3 billion SEK. Magnus has managed or supervised 40+ product developments projects from start to regulatory approved and launched globally. Magnus previously served as CEO of Stockholms Tekniska Institut, an engineering school with 350+ students managing a turnaround operationally and strategically.

Stuart McConchie

Born: 1952
Education: Pharmacology – Monash University, Melbourne, Australia.
Board of Director assignments: Stuart has no current board positions.
Experience: Stuart has held senior positions in global medical device companies for more than 25 years, guiding companies from research to product commercialisation. Stuart has worked with several heart pump companies, most recently as CEO of UK-based Calon Cardio Technology, and previously with US-based Jarvik Heart and Australian HeartWare Inc where he also gained experience in a publicly traded environment before the company was acquired by Medtronic. Stuart has extensive regulatory experience, including FDA interaction with multiple products.

Giovanni Lauricella

Born: 1987

Education: Bachelor of Science (BSc) in Finance, a Master of Science (MSc) in Regulatory Affairs in Medical Devices, a Harvard University Certificate in Advanced Negotiation Strategy and a Universita Bocconi Certificate in Private Equity and Venture Capital.

Board of Director assignments: Managing partner at Lifeblood Inc., specializing in recruitment and fund raising for medtech companies.

Experience Giovanni has worked with over 500 startups worldwide and is currently member of several boards. He also organizes the conference Med-Tech World, which gathers around 3,000 participants, bringing together companies with investors, industry, and the media. He runs the podcast MedTech Money which focuses on demystifying raising and investing capital for Medtech startups.

Item 8 – Determination of fees for Board members

The Nomination Committee proposes that board fees for each of the new members according to item 7 above shall be paid with SEK 72,500.

Information on the number of shares and votes

At the time of issue of this notice, the total number of shares and votes in the Company amounts to 96,994,446.

Shareholders' right to request information

The shareholders are reminded of their right, in accordance with Chapter 7 Section 32 of the Swedish Companies Act (2005:551), to request information from the Board Directors and the CEO at the Meeting.

Provision of documents

Proxy forms as well as other documents required by the Companies Act will be kept available to the shareholders at the Company's head office; Kopparbergsvägen 6, 722 13 Västerås and on the Company's website www.realheart.se.

Copies of the documents will also be sent to shareholders who so request and who provide their postal address.

Västerås in November 2023
Scandinavian Real Heart AB
THE BOARD OF DIRECTORS

Kallelse till extra bolagsstämma i Scandinavian Real Heart AB

Pressmeddelande, 2023-11-08

Aktieägarna i Scandinavian Real Heart AB, org.nr. 556729-5588 ("Bolaget"), kallas härmed till årsstämma fredagen den 24 november 2023 kl. 10.00 på Best Western Plus Hotel Plaza, Kopparbergsvägen 10, 722 13 Västerås. Inregistrering till stämman börjar kl. 9.30.

Rätt att delta vid stämman m.m.

Aktieägare som önskar delta vid stämman ska

  • dels vara införd i den av Euroclear Sweden AB förda aktieboken senast torsdagen den 16 november 2023, och
  • dels anmäla sig till Bolaget senast måndagen den 20 november 2023 per post till Scandinavian Real Heart AB, Kopparbergsvägen 6, 722 13 Västerås, per telefon 070-643 88 61 eller per e-post jonas.bark@realheart.se.I anmälan ska uppges fullständigt namn, person- eller organisationsnummer, aktieinnehav, adress, telefonnummer dagtid samt, i förekommande fall, uppgift om ställföreträdare eller biträden (högst två).

För att ha rätt att delta i stämman måste en aktieägare som låtit förvaltarregistrera sina aktier, förutom att anmäla sig till stämman, låta registrera aktierna i eget namn så att aktieägaren blir upptagen i framställningen av aktieboken per avstämningsdagen torsdagen den 16 november 2023. Sådan omregistrering kan vara tillfällig (s.k. rösträttsregistrering) och begärs hos förvaltaren enligt förvaltarens rutiner i sådan tid i förväg som förvaltaren bestämmer. Rösträttsregistrering som gjorts av förvaltaren senast måndagen den 20 november 2023 kommer att beaktas vid framställningen av bolagsstämmoaktieboken.

Ombud m.m.

Om aktieägare ska företrädas av ombud måste ombudet ha med skriftlig, daterad och av aktieägaren undertecknad fullmakt till stämman. Fullmakten får inte vara äldre än ett år om den inte anger att den är giltig under en längre tid, dock längst fem år. Om fullmakten utfärdats av juridisk person ska ombudet också ha med aktuellt registreringsbevis eller motsvarande behörighetshandling för den juridiska personen. För att underlätta inpasseringen bör kopia av fullmakt och andra behörighetshandlingar bifogas anmälan till stämman. Fullmaktsformulär hålls tillgängligt på Bolagets hemsida www.realheart.se och skickas med post till aktieägare som kontaktar Bolaget och uppger sin adress.

Behandling av personuppgifter

För information om hur personuppgifter behandlas i samband med bolagsstämman hänvisas till den integritetspolicy som finns tillgänglig på Euroclear Sweden ABs hemsida: https://www.euroclear.com/dam/ESw/Legal/Integritetspolicy-bolagsstammor-svenska.pdf.

Förslag till dagordning

1.
 Val av ordförande vid stämman

2.
 Val av en eller två justeringspersoner

3.
 Upprättande och godkännande av röstlängd

4.
 Godkännande av dagordning

5.
 Prövning av om stämman blivit behörigen sammankallad

6.
 Fastställande av antalet styrelseledamöter

7.
 Val av styrelseledamöter

8.
 Fastställande av arvoden till styrelsen

9.
 Stämmans avslutande

Valberedningens beslutsförslag

Punkt 1 – Val av ordförande vid stämman

Valberedningen består, fram till årsstämman 2024 av Kim Norström och Azad Najar enligt beslut av årsstämman 2023. Valberedningen föreslår att Christer Norström, eller den som valberedningen utser vid dennes förhinder, utses till ordförande vid den extra bolagsstämman.

Punkt 6 – Fastställande av antalet styrelseledamöter

Valberedningen föreslår att styrelsen ska bestå av åtta ordinarie styrelseledamöter utan suppleanter.

Punkt 7 – Val av styrelseledamöter

Valberedningen föreslår, för tiden intill slutet av nästa årsstämma, att nuvarande styrelse ska kompletteras med följande nya ledamöter: Magnus Öhman, Stuart McConchie och Giovanni Lauricella. Styrelsen består i övrigt av ledamöterna Christer Norström, tillika styrelsens ordförande, Azad Najar, Ulf Grape, Oliver Voigt och Solveig Bergström som styrelseledamöter.

Magnus Öhman

Född: 1961

Utbildning: Civilingenjörsexamen i maskinteknik

Styrelseuppdrag: Magnus är för närvarande styrelseordförande i Neosense Technologies, ett svenskt nystartat medicintekniskt företag som utvecklar invasiva sensorbaserade produkter där den första produkten avsevärt förbättrar kontinuerlig syreövervakning för neonatala barn för att förbättra överlevnadsgraden och livskvaliteten. Han har varit styrelseledamot i Stockholms Tekniska Institut, en ingenjörsskola som grundades 1924.

Erfarenhet: Magnus har över 30 års erfarenhet från medicinteknik inklusive FoU-ledarskap med både lokalt och globalt ansvar och som VD för St Jude Medicals CRM-dotterbolag med FoU, tillverkning och distributionsverksamhet med över 600 anställda och en omsättning på 5,3 miljarder SEK. Magnus har lett eller övervakat 40+ produktutvecklingsprojekt från start till regulatoriskt godkännande och lansering globalt.

Magnus har tidigare varit VD för Stockholms Tekniska Institut, en ingenjörsskola med 350+ studenter som genomförde en turnaround både operativt och strategiskt.

Stuart McConchie

Född: 1952

Utbildning: Farmakologi – Monash University, Melbourne, Australien.

Styrelseuppdrag: Stuart har inga pågående styrelseuppdrag.

Erfarenhet: Stuart har i mer än 25 år haft toppositioner i globala medicinteknikföretag, och lotsat bolag från forskning till kommersialisering av produkter. Stuart har arbetat med flera hjärtpumpsföretag, senast som VD för brittiska Calon Cardio Technology, och tidigare hos amerikanska Jarvik Heart och Australian HeartWare Inc där han också fick erfarenhet från noterad miljö innan bolaget förvärvades av Medtronic. Stuart har omfattande erfarenhet från regulatoriska frågor, inkluderande FDA-interaktion med ett flertal produkter.

Giovanni Lauricella

Född: 1987

Utbildning: Bachelorexamen (BSc) i Finance, masterexamen (MSc) i Regulatory Affairs med inriktning på medicinteknik, samt en fördjupad akademisk bakgrund inom avancerad förhandlingsstrategi vid Harvard University och inom Private Equity och Venture Capital vid Universita Bocconi.

Styrelseuppdrag: Managing Partner på Lifeblood Inc., ett bolag med specialistkompetens inom rekrytering och kapitalanskaffning till medicintekniska företag.

Erfarenhet: Giovanni har arbetat med över 500 start up-bolag världen över och är idag ledamot i flera bolagsstyrelser. Han organiserar även konferensen Med-Tech World, med över 3 000 deltagare årligen, för att föra samman bolag med investerare, industri och media. Han driver även podcasten MedTech Money som fokuserar på att avmystifiera kapitalanskaffning och investeringar i medicintekniska start up-bolag.

Punkt 8 – Fastställande av arvoden åt styrelsen

Valberedningen föreslår att styrelsearvode för var och en av de nya ledamöterna enligt punkt 7 ovan ska utgå med 72 500 kronor.

Uppgifter om antalet aktier och röster

Vid tidpunkten för denna kallelses utfärdande uppgår det totala antalet aktier och röster i Bolaget till 96 994 446 stycken.

Aktieägares rätt att erhålla upplysningar

Aktieägarna erinras om rätten att vid stämman begära upplysningar från styrelsen och verkställande direktören i enlighet med 7 kap. 32 § aktiebolagslagen (2005:551).

Tillhandahållande av handlingar

Fullmaktsformulär och övriga handlingar enligt aktiebolagslagen hålls tillgängliga hos Bolaget och tillsändes utan kostnad den aktieägare som begär det och uppger sin postadress. Handlingarna hålls även tillgängliga på Bolagets huvudkontor; Kopparbergsvägen 6, 722 13 Västerås samt på Bolagets hemsida www.realheart.se.

Handlingarna skickas också till de aktieägare som begär det och som uppger sin postadress.

Västerås i november 2023
Scandinavian Real Heart AB
STYRELSEN

Realheart Performs a Directed Issue to EIC in Connection With the Completed Rights Issue

Press Release July 26, 2023

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE FURTHER REGISTRATION OR ANY OTHER MEASURES.

Scandinavian Real Heart AB ("Realheart" or the "Company") announces that the Company's board of directors, based on the authorization from the annual general meeting on June 14, 2023, has resolved to issue 9 150 000 units to the European Innovation Council ("EIC") Accelerator, in accordance with the investment agreement announced on May 15, 2023. The directed issue consists of 9 150 000 units of the same type and on the same terms as the units in the rights issue announced on the same day and Realheart thus receives an additional SEK 14 640 000 before transaction costs. After the directed issue, the total number of shares will increase from 78 694 446 shares (after registration of the rights issue and the directed issue to underwriters) with 18 300 000 shares to a total of 96 994 446 shares. The EIC will then hold 18,9 of total shares and votes in the company.

The Company had received subscription commitments from EIC based on the following conditions:

– The investment is a co-investment with new and existing shareholders.

– That the investment corresponds to one third of the total capital raising, i.e. the rights issue and the directed issue combined, but that EIC's total ownership does not exceed 20 percent of the company after the investment has been completed.

Through the directed issue to EIC the Company's share capital increases by SEK 1 830 000.0 from SEK 7 869 444.60 after the rights issue and the directed issue to underwriters to SEK 9 699 444.60. Through the directed issue to EIC 9 150 000 warrants of series TO2 are also issued, which entitle the holder to subscribe for 4 575 000 shares in the Company. Upon full exercise of the Warrants, the share capital will increase by a maximum of SEK 457 500.0 and the number of shares will increase by a maximum of 4 575 000 shares.

Total increase in number of shares and share capital

In total the number of shares in Realheart after the rights issue, the directed issue to the underwriters and the directed issue to EIC (jointly the "Issues") increases by 62 015 198 shares from 34 979 248 shares to 96 994 446 shares, and the share capital increases by SEK 6 201 519.80 from SEK 3 497 924.8 to SEK 9 699 444.60. This gives a dilution effect of approximately 63.9 percent of the votes and capital in the Company.

Through the Issues, a total of 31 007 599 warrants of series TO2 are issued, which entitle the holders to subscribe for a maximum of 15 503 799 shares in the Company. Upon full exercise of the warrants, the share capital will increase by an additional maximum of SEK 1 550 379.90. This corresponds to a dilution effect from the Warrants of an additional maximum of approximately 13.8 percent of the votes and capital in the Company.

Advisers

Skills Corporate Finance Nordic AB is financial adviser and Setterwalls Advokatbyrå AB is legal adviser to Realheart in connection with the Rights Issue.

Important information

Publication, release, or distribution of this press release may in certain jurisdictions be subject to legal restrictions and persons in the jurisdictions where this press release has been made public or distributed should inform themselves of and follow such legal restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with applicable rules in each jurisdiction.

The information in this press release neither contains nor constitutes an offer to acquire, subscribe for or otherwise trade shares, warrants or other securities in Realheart. No action has been taken and no action will be taken to allow an offer to the public in any jurisdiction other than Sweden. The Swedish Financial Supervisory Authority's approval of the Prospectus shall not be construed as an approval of the Company's shares, warrants or other securities. However, this press release is not a prospectus within the meaning of the Prospectus Regulation (EU) 2017/1129 ("Prospectus Regulation"), and this press release neither identifies nor purports to identify risks (direct or indirect) that may be associated with an investment in shares, warrants or other securities in Realheart. The information in this press release is only intended to describe the background to the Rights Issue and does not claim to be complete or exhaustive. No assurance shall be given with respect to the accuracy or completeness of the information in this press release. Any investment decision should, in order for an investor to fully understand the potential risks and benefits associated with the decision to participate in the Rights Issue, be based solely on the information in the Prospectus. Therefore, an investor is recommended to read the entire Prospectus. This press release constitutes marketing in accordance with Article 2(k) of the Prospectus Regulation.

The information in this press release may not be published, released or distributed, directly or indirectly, in or to the United States, Australia, Belarus, Hong Kong, Japan, Canada, New Zealand, Russia, Switzerland, Singapore, South Africa, South Korea or any other jurisdiction where such action would be unlawful, subject to legal restrictions or require other actions than those following from Swedish law. Actions in violation of this instruction may constitute violations of applicable securities laws. No shares, warrants or other securities in Realheart have been registered, and no shares, warrants or other securities will be registered, under the then-applicable United States Securities Act of 1933 (the "Securities Act") or securities legislation in any state or other jurisdiction in the United States, and may not be offered, sold or otherwise transferred, directly or indirectly, in or to the United States except in accordance with an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in accordance with securities legislation in the relevant state or other jurisdiction in the United States.

In the United Kingdom, this document and any other materials in relation to the securities described herein is only being distributed to, and is only directed at, and any investment or investment activity to which this document relates is available only to, and will be engaged in only with, “qualified investors” who are (i) persons having professional experience in matters relating to investments who fall within the definition of “investment professionals” in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”); or (ii) high net worth entities falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as “relevant persons”). In the United Kingdom, any investment or investment activity to which this communication relates is available only to, and will be engaged in only with, relevant persons. Persons who are not relevant persons should not take any action on the basis of this press release and should not act or rely on it.

Realheart genomför riktad emission till EIC i samband med den genomförda företrädesemissionen

Pressmeddelande, 2023-07-26

EJ FÖR OFFENTLIGGÖRANDE, DISTRIBUTION ELLER PUBLICERING, VARKEN DIREKT ELLER INDIREKT, INOM ELLER TILL USA, AUSTRALIEN, BELARUS, HONGKONG, JAPAN, KANADA, NYA ZEELAND, RYSSLAND, SCHWEIZ, SINGAPORE, SYDAFRIKA, SYDKOREA ELLER I NÅGON ANNAN JURISDIKTION DÄR OFFENTLIGGÖRANDE, DISTRIBUTION ELLER PUBLICERING AV DETTA PRESSMEDDELANDE SKULLE VARA OLAGLIG ELLER KRÄVA YTTERLIGARE REGISTRERINGS- ELLER ANDRA ÅTGÄRDER.

Scandinavian Real Heart AB ("Realheart" eller "Bolaget") meddelar att Bolagets styrelse, med stöd av bemyndigandet från årsstämman den 14 juni 2023, beslutat om att emittera 9 150 000 units till European Innovation Council (”EIC”) Accelerator, i enlighet med den överenskommelse om investering som offentliggjordes den 15 maj 2023. Den riktade emissionen består av 9 150 000 units av samma typ och till samma villkor som i företrädesemissionen som offentliggjordes samma dag. Realheart tillförs därmed ytterligare 14 640 000 kronor före transaktionskostnader. Efter den riktade emissionen kommer det totala antalet aktier att öka från 78 694 446 aktier (efter registrering av företrädesemissionen och den riktade emissionen till garanter) med 18 300 000 aktier till totalt 96 994 446 aktier. Efter emissionen kommer EIC att äga 18,8 procent av aktierna och rösterna i Bolaget.

Bolaget hade erhållit teckningsåtaganden från EIC baserat på följande villkor:

– Investeringen är en saminvestering med nya och befintliga aktieägare.

– Att investeringen motsvarar en tredjedel av den totala kapitalanskaffningen, dvs företrädesemissionen och den riktade emissionen sammantaget, men att EIC:s totala ägande inte överstiger 20 procent av företaget efter att investeringen har slutförts.

Den riktade emissionen till EIC innebär en ökning av Bolagets aktiekapital med 1 830 000,0 kronor från 7 869 444,60 kronor efter företrädesemissionen och den riktade emissionen till garanter till 9 699 444,60 kronor. Genom den riktade emissionen till EIC emitteras även 9 150 000 teckningsoptioner av serie TO2, vilka berättigar till teckning av 4 575 000 aktier i Bolaget. Vid fullt utnyttjande av Teckningsoptionerna ökar aktiekapitalet med ytterligare högst 457 500,0 kronor och antalet aktier ökar med högst 4 575 000 aktier.

Total ökning av antal aktier och aktiekapital

Sammantaget medför företrädesemissionen, den riktade emissionen till garanterna och den riktade Emissionen till EIC (gemensamt ”Emissionerna”) att antalet aktier i Realheart ökar med 62 015 198 aktier från 34 979 248 aktier till 96 994 446 aktier, och att aktiekapitalet ökar med 6 201 519,80 kronor från 3 497 924,8 kronor till 9 699 444,60 kronor. Detta motsvarar en utspädningseffekt om cirka 63,9 procent av röster och kapital i Bolaget.

För det fall samtliga Teckningsoptioner som emitterats genom Emissionerna utnyttjas fullt ut för teckning av nya aktier i Bolaget, kommer antalet aktier att öka med ytterligare högst 15 503 799 aktier och aktiekapitalet kommer att öka med ytterligare högst 1 550 379,90 kronor. Detta motsvarar en utspädningseffekt från Teckningsoptionerna om ytterligare högst cirka 13,8 procent av röster och kapital i Bolaget.

Rådgivare

Skills Corporate Finance Nordic AB är finansiell rådgivare 0ch Setterwalls Advokatbyrå AB är legal rådgivare till Realheart i samband med Företrädesemissionen. Nordic Issuing AB agerar emissionsinstitut.

Viktig information

Publicering, offentliggörande eller distribution av detta pressmeddelande kan i vissa jurisdiktioner vara föremål för restriktioner enligt lag och personer i de jurisdiktioner där detta pressmeddelande har offentliggjorts eller distribuerats bör informera sig om och följa sådana legala restriktioner. Mottagaren av detta pressmeddelande ansvarar för att använda detta pressmeddelande och informationen häri i enlighet med tillämpliga regler i respektive jurisdiktion.

Informationen i detta pressmeddelande varken innehåller eller utgör ett erbjudande att förvärva, teckna eller på annat sätt handla med aktier, teckningsoptioner eller andra värdepapper i Realheart. Ingen åtgärd har vidtagits och åtgärder kommer inte att vidtas för att tillåta ett erbjudande till allmänheten i några andra jurisdiktioner än Sverige. Finansinspektionens godkännande av Prospektet ska inte uppfattas som ett godkännande av Bolagets aktier, teckningsoptioner eller andra värdepapper. Detta pressmeddelande är dock inte ett prospekt enligt betydelsen i Prospektförordningen (EU) 2017/1129 (”Prospektförordningen”) och detta pressmeddelande varken identifierar eller utger sig för att identifiera risker (direkta eller indirekta) som kan vara förbundna med en investering i aktier, teckningsoptioner eller andra värdepapper i Realheart. Informationen i detta pressmeddelande är endast till för att beskriva bakgrunden till Företrädesemissionen och gör inget anspråk på att vara fullständigt eller uttömmande. Ingen försäkran ska lämnas med anledning av informationen i detta pressmeddelande avseende dess noggrannhet eller fullständighet. Eventuellt investeringsbeslut bör, för att en investerare fullt ut ska förstå de potentiella riskerna och fördelarna som är förknippade med beslutet att delta i Företrädesemissionen, enbart fattas baserat på informationen i Prospektet. Därmed rekommenderas en investerare att läsa hela Prospektet. Detta pressmeddelande utgör marknadsföring i enlighet med artikel 2 k i Prospektförordningen.

Informationen i detta pressmeddelande får inte offentliggöras, publiceras eller distribueras, direkt eller indirekt, inom eller till USA, Australien, Belarus, Hongkong, Japan, Kanada, Nya Zeeland, Ryssland, Schweiz, Singapore, Sydafrika, Sydkorea eller någon annan jurisdiktion där sådan åtgärd skulle vara olaglig, föremål för legala restriktioner eller kräva andra åtgärder än de som följer av svensk rätt. Åtgärder i strid med denna anvisning kan utgöra brott mot tillämplig värdepapperslagstiftning. Inga aktier, teckningsoptioner eller andra värdepapper i Realheart har registrerats, och inga aktier, teckningsoptioner eller andra värdepapper kommer att registreras, enligt den vid var tid gällande United States Securities Act från 1933 (”Securities Act”) eller värdepapperslagstiftningen i någon delstat eller annan jurisdiktion i USA och får inte erbjudas, säljas eller på annat sätt överföras, direkt eller indirekt, i eller till USA, förutom i enlighet med ett tillämpligt undantag från, eller i en transaktion som inte omfattas av, registreringskraven i Securities Act och i enlighet med värdepapperslagstiftningen i relevant delstat eller annan jurisdiktion i USA.

I Storbritannien distribueras och riktas detta dokument, och annat material avseende värdepapperen som omnämns häri, endast till, och en investering eller investeringsaktivitet som är hänförlig till detta dokument är endast tillgänglig för och kommer endast att kunna utnyttjas av, "kvalificerade investerare" som är (i) personer som har professionell erfarenhet av verksamhet som rör investeringar och som faller inom definitionen av "professionella investerare" i artikel 19(5) i den brittiska Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 ("Ordern"); eller (ii) personer med hög nettoförmögenhet som avses i artikel 49(2)(a)-(d) i Ordern (alla sådana personer benämns gemensamt "relevanta personer"). En investering eller en investeringsåtgärd som detta meddelande avser är i Storbritannien enbart tillgänglig för relevanta personer och kommer endast att genomföras med relevanta personer. Personer som inte är relevanta personer ska inte vidta några åtgärder baserat på detta pressmeddelande och inte heller agera eller förlita sig på det.

Realheart genomför riktad nyemission av units till garanter i samband med den genomförda företrädesemissionen

Pressmeddelande, 2023-07-26

EJ FÖR OFFENTLIGGÖRANDE, DISTRIBUTION ELLER PUBLICERING, VARKEN DIREKT ELLER INDIREKT, INOM ELLER TILL USA, AUSTRALIEN, BELARUS, HONGKONG, JAPAN, KANADA, NYA ZEELAND, RYSSLAND, SCHWEIZ, SINGAPORE, SYDAFRIKA, SYDKOREA ELLER I NÅGON ANNAN JURISDIKTION DÄR OFFENTLIGGÖRANDE, DISTRIBUTION ELLER PUBLICERING AV DETTA PRESSMEDDELANDE SKULLE VARA OLAGLIG ELLER KRÄVA YTTERLIGARE REGISTRERINGS- ELLER ANDRA ÅTGÄRDER.

Scandinavian Real Heart AB ("Realheart" eller "Bolaget") meddelar att Bolagets styrelse, med stöd av bemyndigandet från årsstämman den 14 juni 2023, beslutat om att emittera 642 950 units som garantiersättning riktat till ett antal av de garanter som lämnade garantiåtaganden i den företrädesemission av units som Bolaget genomförde under perioden 20 juni till och med den 7 juli 2023, i enlighet med de garantiavtal som ingåtts.

De garanter som lämnade garantiåtaganden i företrädesemissionen hade möjlighet att välja att få ersättningen utbetalad kontant eller i form av nyemitterade units i Bolaget, vilket tidigare kommunicerats i samband med företrädesemissionen. Sammanlagt har åtta garanter valt att få garantiersättningen utbetalad i units. Bolagets styrelse har med anledning därav beslutat, med stöd av bemyndigandet från årsstämman den 14 juni 2023, om att emittera 642 950 units som ersättning till dessa garanter, vilket kommer öka Bolagets aktiekapital med cirka 128 590,00 SEK. Syftet med den riktade emissionen och skälet till avvikelsen från aktieägarnas företrädesrätt är således att uppfylla Bolagets åtaganden gentemot garanterna i enlighet med ingångna garantiavtal.

Units emitteras till en kurs om 1,6 SEK per unit, motsvarande 0,80 SEK per aktie, vilket motsvarar teckningskursen i företrädesemissionen. Styrelsen har beslutat att betalning för units ska ske genom kvittning av respektive garants fordran på Bolaget. Totalt uppgår garanternas fordran till 1 028 726,72 SEK. När dessa 642 950 units tillsammans med de 21 214 649 units som emitterades i företrädesemissionen har registrerats hos Bolagsverket kommer antalet aktier i Bolaget att uppgå till 78 694 446 aktier och Bolagets aktiekapital till cirka 7 869 444,60 SEK. Den utspädning som tillkommer som följd av den riktade emissionen till garanterna uppgår till cirka 1,6 procent efter att företrädesemissionen har registrerats.

Genom den riktade emissionen till garanterna emitteras även 642 950 teckningsoptioner av serie TO2, vilka berättigar till teckning av högst 321 475 aktier i Bolaget. Vid fullt utnyttjande av Teckningsoptionerna ökar aktiekapitalet med ytterligare högst 32 147,50 kronor.

Bolaget har inte haft några specifika kostnader relaterade till den riktade emissionen då denna sker som en del i arbetet med företrädesemissionen.

Rådgivare

Skills Corporate Finance Nordic AB är finansiell rådgivare och Setterwalls Advokatbyrå AB är legal rådgivare till Realheart i samband med företrädesemissionen.

Viktig information

Publicering, offentliggörande eller distribution av detta pressmeddelande kan i vissa jurisdiktioner vara föremål för restriktioner enligt lag och personer i de jurisdiktioner där detta pressmeddelande har offentliggjorts eller distribuerats bör informera sig om och följa sådana legala restriktioner. Mottagaren av detta pressmeddelande ansvarar för att använda detta pressmeddelande och informationen häri i enlighet med tillämpliga regler i respektive jurisdiktion.

Informationen i detta pressmeddelande varken innehåller eller utgör ett erbjudande att förvärva, teckna eller på annat sätt handla med aktier, teckningsoptioner eller andra värdepapper i Realheart. Ingen åtgärd har vidtagits och åtgärder kommer inte att vidtas för att tillåta ett erbjudande till allmänheten i några andra jurisdiktioner än Sverige. Finansinspektionens godkännande av Prospektet ska inte uppfattas som ett godkännande av Bolagets aktier, teckningsoptioner eller andra värdepapper. Detta pressmeddelande är dock inte ett prospekt enligt betydelsen i Prospektförordningen (EU) 2017/1129 (”Prospektförordningen”) och detta pressmeddelande varken identifierar eller utger sig för att identifiera risker (direkta eller indirekta) som kan vara förbundna med en investering i aktier, teckningsoptioner eller andra värdepapper i Realheart. Informationen i detta pressmeddelande är endast till för att beskriva bakgrunden till Företrädesemissionen och gör inget anspråk på att vara fullständigt eller uttömmande. Ingen försäkran ska lämnas med anledning av informationen i detta pressmeddelande avseende dess noggrannhet eller fullständighet. Eventuellt investeringsbeslut bör, för att en investerare fullt ut ska förstå de potentiella riskerna och fördelarna som är förknippade med beslutet att delta i Företrädesemissionen, enbart fattas baserat på informationen i Prospektet. Därmed rekommenderas en investerare att läsa hela Prospektet. Detta pressmeddelande utgör marknadsföring i enlighet med artikel 2 k i Prospektförordningen.

Informationen i detta pressmeddelande får inte offentliggöras, publiceras eller distribueras, direkt eller indirekt, inom eller till USA, Australien, Belarus, Hongkong, Japan, Kanada, Nya Zeeland, Ryssland, Schweiz, Singapore, Sydafrika, Sydkorea eller någon annan jurisdiktion där sådan åtgärd skulle vara olaglig, föremål för legala restriktioner eller kräva andra åtgärder än de som följer av svensk rätt. Åtgärder i strid med denna anvisning kan utgöra brott mot tillämplig värdepapperslagstiftning. Inga aktier, teckningsoptioner eller andra värdepapper i Realheart har registrerats, och inga aktier, teckningsoptioner eller andra värdepapper kommer att registreras, enligt den vid var tid gällande United States Securities Act från 1933 (”Securities Act”) eller värdepapperslagstiftningen i någon delstat eller annan jurisdiktion i USA och får inte erbjudas, säljas eller på annat sätt överföras, direkt eller indirekt, i eller till USA, förutom i enlighet med ett tillämpligt undantag från, eller i en transaktion som inte omfattas av, registreringskraven i Securities Act och i enlighet med värdepapperslagstiftningen i relevant delstat eller annan jurisdiktion i USA.

I Storbritannien distribueras och riktas detta dokument, och annat material avseende värdepapperen som omnämns häri, endast till, och en investering eller investeringsaktivitet som är hänförlig till detta dokument är endast tillgänglig för och kommer endast att kunna utnyttjas av, "kvalificerade investerare" som är (i) personer som har professionell erfarenhet av verksamhet som rör investeringar och som faller inom definitionen av "professionella investerare" i artikel 19(5) i den brittiska Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 ("Ordern"); eller (ii) personer med hög nettoförmögenhet som avses i artikel 49(2)(a)-(d) i Ordern (alla sådana personer benämns gemensamt "relevanta personer"). En investering eller en investeringsåtgärd som detta meddelande avser är i Storbritannien enbart tillgänglig för relevanta personer och kommer endast att genomföras med relevanta personer. Personer som inte är relevanta personer ska inte vidta några åtgärder baserat på detta pressmeddelande och inte heller agera eller förlita sig på det.

Realheart Performs a Directed Issue of Units to Underwriters in Connection With the Completed Rights Issue

Press Release July 26, 2023

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY,  WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE FURTHER REGISTRATION OR ANY OTHER MEASURES.

Scandinavian Real Heart AB ("Realheart" or the "Company") announces that the Company's board, with the support of the authorization from the annual general meeting on June 14, 2023, has resolved to issue 642 950 units as underwriting compensation directed to a number of the underwriters who provided underwriting commitments in the rights issue that the Company carried out during the period June 20 to July 7, 2023, in accordance with the underwriting agreements entered into.

The underwriters who provided underwriting commitments in the rights issue had the option of having the compensation paid out in cash or in the form of issued units in the Company, which was previously communicated in connection with the rights issue. In total, eight underwriters have chosen to have the underwriting compensation paid out in units. The Company's board has therefore resolved, with the support of the authorization from the annual general meeting on June 14, 2023, to issue 642 950 units as compensation to these underwriters, which will increase the company's number of shares by 1 285 900 shares and the company’s share capital by approximately 128 590.00 SEK. The purpose of the directed issue and the reason for the deviation from the shareholders’ preferential rights is thus to fulfill the Company’s commitments to the underwriters in accordance with the underwriting agreements.

Units are issued at a price of 1.6 SEK per unit, corresponding to 0.80 SEK per share, which corresponds to the pricing of shares and units in the rights issue.  The board has resolved that payment for units shall be made by offsetting the respective underwriter's claim on the Company. The underwriters’ total claim amounts to 1 028 726,72 SEK. When these 642 950 units together with the 21 214 649 units that were issued in the rights issue have been registered with the Swedish Companies Registration Office, the number of shares in the Company will amount to 78 694 446 shares, and the Company's share capital to approximately 7 869 444,60 SEK. The dilution that accrues as a result of the directed issue to the underwriters amounts to approximately 1.6 percent after the rights issue has been registered.

Through the directed issue to the underwriters, 642 950 warrants of series TO2 are issued, which entitle the holder to subscribe for a maximum of 321 475 shares in the Company. Upon full exercise of the warrants, the share capital will increase by an additional maximum of SEK 32 147.50.

The Company has had no specific costs related to the directed issue as this takes place as part of the work with the rights issue.

Advisers

Skills Corporate Finance Nordic AB is financial adviser and Setterwalls Advokatbyrå AB is legal adviser to Realheart in connection with the Rights Issue.

Important information

Publication, release, or distribution of this press release may in certain jurisdictions be subject to legal restrictions and persons in the jurisdictions where this press release has been made public or distributed should inform themselves of and follow such legal restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with applicable rules in each jurisdiction.

The information in this press release neither contains nor constitutes an offer to acquire, subscribe for or otherwise trade shares, warrants or other securities in Realheart. No action has been taken and no action will be taken to allow an offer to the public in any jurisdiction other than Sweden. The Swedish Financial Supervisory Authority's approval of the Prospectus shall not be construed as an approval of the Company's shares, warrants or other securities. However, this press release is not a prospectus within the meaning of the Prospectus Regulation (EU) 2017/1129 ("Prospectus Regulation"), and this press release neither identifies nor purports to identify risks (direct or indirect) that may be associated with an investment in shares, warrants or other securities in Realheart. The information in this press release is only intended to describe the background to the Rights Issue and does not claim to be complete or exhaustive. No assurance shall be given with respect to the accuracy or completeness of the information in this press release. Any investment decision should, in order for an investor to fully understand the potential risks and benefits associated with the decision to participate in the Rights Issue, be based solely on the information in the Prospectus. Therefore, an investor is recommended to read the entire Prospectus. This press release constitutes marketing in accordance with Article 2(k) of the Prospectus Regulation.

The information in this press release may not be published, released or distributed, directly or indirectly, in or to the United States, Australia, Belarus, Hong Kong, Japan, Canada, New Zealand, Russia, Switzerland, Singapore, South Africa, South Korea or any other jurisdiction where such action would be unlawful, subject to legal restrictions or require other actions than those following from Swedish law. Actions in violation of this instruction may constitute violations of applicable securities laws. No shares, warrants or other securities in Realheart have been registered, and no shares, warrants or other securities will be registered, under the then-applicable United States Securities Act of 1933 (the "Securities Act") or securities legislation in any state or other jurisdiction in the United States, and may not be offered, sold or otherwise transferred, directly or indirectly, in or to the United States except in accordance with an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in accordance with securities legislation in the relevant state or other jurisdiction in the United States.

In the United Kingdom, this document and any other materials in relation to the securities described herein is only being distributed to, and is only directed at, and any investment or investment activity to which this document relates is available only to, and will be engaged in only with, “qualified investors” who are (i) persons having professional experience in matters relating to investments who fall within the definition of “investment professionals” in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”); or (ii) high net worth entities falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as “relevant persons”). In the United Kingdom, any investment or investment activity to which this communication relates is available only to, and will be engaged in only with, relevant persons. Persons who are not relevant persons should not take any action on the basis of this press release and should not act or rely on it.

Kallelse till årsstämma i Scandinavian Real Heart AB

Pressmeddelande, 2023-05-16

Aktieägarna i Scandinavian Real Heart AB, org.nr. 556729–5588 (”Bolaget”), kallas härmed till årsstämma onsdagen den 14 juni 2023 kl. 15.00 på Best Western Plus Hotel Plaza, Kopparbergsvägen 10, 722 13 Västerås. Inregistrering till stämman börjar kl. 14.30.

Rätt att delta vid stämman m.m.

Aktieägare som önskar delta vid stämman ska

  • dels vara införd i den av Euroclear Sweden AB förda aktieboken senast måndagen den 5 juni 2023, och
  • dels anmäla sig till Bolaget senast torsdagen den 8 juni 2023 per post till Scandinavian Real Heart AB, Kopparbergsvägen 10, 722 13 Västerås, per telefon 070-643 88 61 eller per e-post jonas.bark@realheart.se. I anmälan ska uppges fullständigt namn, person- eller organisationsnummer, aktieinnehav, adress, telefonnummer dagtid samt, i förekommande fall, uppgift om ställföreträdare eller biträden (högst två).

För att ha rätt att delta i stämman måste en aktieägare som låtit förvaltarregistrera sina aktier, förutom att anmäla sig till stämman, låta registrera aktierna i eget namn så att aktieägaren blir upptagen i framställningen av aktieboken per avstämningsdagen måndagen den 5 juni 2023. Sådan omregistrering kan vara tillfällig (s.k. rösträttsregistrering) och begärs hos förvaltaren enligt förvaltarens rutiner i sådan tid i förväg som förvaltaren bestämmer. Rösträttsregistrering som gjorts av förvaltaren senast torsdagen den 8 juni 2023 kommer att beaktas vid framställningen av bolagsstämmoaktieboken.

Ombud m.m.

Om aktieägare ska företrädas av ombud måste ombudet ha med skriftlig, daterad och av aktieägaren undertecknad fullmakt till stämman. Fullmakten får inte vara äldre än ett år om den inte anger att den är giltig under en längre tid, dock längst fem år. Om fullmakten utfärdats av juridisk person ska ombudet också ha med aktuellt registreringsbevis eller motsvarande behörighetshandling för den juridiska personen. För att underlätta inpasseringen bör kopia av fullmakt och andra behörighetshandlingar bifogas anmälan till stämman. Fullmaktsformulär hålls tillgängligt på Bolagets hemsida www.realheart.se och skickas med post till aktieägare som kontaktar Bolaget och uppger sin adress.

Behandling av personuppgifter

För information om hur personuppgifter behandlas i samband med bolagsstämman hänvisas till den integritetspolicy som finns tillgänglig på Euroclear Sweden ABs hemsida: https://www.euroclear.com/dam/ESw/Legal/Integritetspolicy-bolagsstammor-svenska.pdf.

Förslag till dagordning

  1. Val av ordförande vid stämman
  2. Val av en eller två justeringspersoner
  3. Upprättande och godkännande av röstlängd
  4. Godkännande av dagordning
  5. Prövning av om stämman blivit behörigen sammankallad
  6. Framläggande av årsredovisning och revisionsberättelse
  7. Beslut
  1. om fastställande av resultaträkning och balansräkning;
  2. om dispositioner beträffande Bolagets resultat enligt den fastställda balansräkningen;
  3. om ansvarsfrihet åt styrelsens ledamöter och verkställande direktören
  1. Fastställande av antalet styrelseledamöter och revisorer
  2. Fastställande av arvoden åt styrelsen och revisor
  3. Val av styrelseledamöter, styrelseordförande samt revisor
  4. Val av valberedning
  5. Beslut om ändring av bolagsordningen
  6. Godkännande av styrelsens beslut om nyemission av units bestående av aktier och teckningsoptioner med företrädesrätt för aktieägarna
  7. Beslut om bemyndigande för styrelsen att besluta om nyemission
  8. Stämmans avslutande

Valberedningens beslutsförslag

Valberedningens förslag avseende val av ordförande till stämman (punkt 1), fastställande av antalet styrelseledamöter och revisorer (punkt 8), fastställande av arvoden åt styrelsen och revisor (punkt 9), val av styrelseledamöter, styrelseordförande samt revisor (punkt 10) samt val av valberedning (punkt 11) kommer att presenteras på Bolagets hemsida www.realheart.se i god tid före stämman. 

Styrelsens beslutsförslag

Punkt 7 b) – Beslut om dispositioner beträffande Bolagets resultat enligt den fastställda balansräkningen

Styrelsen föreslår att årsstämman beslutar att årets resultat balanseras i ny räkning och att ingen utdelning ges för räkenskapsåret 2022.

Punkt 12 – Beslut om ändring av bolagsordningen

Styrelsen föreslår att stämman beslutar om ändring av bolagsordningen i enlighet med nedanstående:

Nuvarande lydelse: Föreslagen lydelse:
§ 4 AktiekapitalAktiekapitalet skall utgöra lägst 2 000 000 kronor och högst 8 000 000 kronor. § 4 AktiekapitalAktiekapitalet skall utgöra lägst 7 000 000 kronor och högst 28 000 000 kronor.
§ 5 Antal aktierAntalet aktier skall vara lägst 20 000 000 och högst 80 000 000 stycken. § 5 Antal aktierAntalet aktier skall vara lägst 70 000 000 och högst 280 000 000 stycken.

Vidare föreslår styrelsen att stämman beslutar om att införa en ny paragraf 11 i bolagsordningen som tillåter att bolagstämma hålls i Västerås eller Stockholm enligt nedan.

Föreslagen lydelse:
§ 11 Ort för bolagsstämmaBolagsstämma ska kunna hållas i Västerås eller Stockholm.

Eftersom det föreslås att paragrafen läggs in som en ny paragraf 11 föreslås även omnumrering av efterföljande paragrafer i bolagsordningen så att tidigare paragraf 11–13 blir paragraf 12–14.

Beslutet ska vara villkorat av att stämman godkänner styrelsens beslut om nyemission av units med företrädesrätt för aktieägarna enligt punkt 13 nedan.

Styrelsen, eller den som styrelsen utser ska bemyndigas att vidta de mindre justeringar i beslutet som kan visa sig erforderliga för registrering av beslutet hos Bolagsverket. För giltigt beslut enligt styrelsens förslag krävs att beslutet biträds av aktieägare som representerar minst två tredjedelar av såväl de avgivna rösterna som de vid stämman företrädda aktierna.

Punkt 13 – Godkännande av styrelsens beslut om nyemission av units bestående av aktier och teckningsoptioner med företrädesrätt för aktieägarna

Styrelsen föreslår att stämman godkänner styrelsens beslut av den 15 maj 2023 om nyemission av så kallade units bestående av nya aktier och teckningsoptioner berättigandes till teckning av nya aktier med företrädesrätt för aktieägarna i enlighet med nedan.

Antal units och aktiekapitalökning

Emissionen omfattar högst 69 958 496 nya aktier och högst 34 979 248 teckningsoptioner av serie TO2, vilka endast ska kunna tecknas och tilldelas i så kallade units där varje unit består av två (2) aktier och en (1) teckningsoption av serie TO2. Efter emissionen kommer dock aktierna och teckningsoptionerna att skiljas åt. Två (2) teckningsoptioner berättigar till teckning av en (1) ny aktie i Bolaget.

Bolagets aktiekapital kommer att kunna ökas genom teckning av de nya aktierna och genom utnyttjande av teckningsoptionerna för nyteckning av aktier. Bolagets aktiekapital kommer att kunna öka med högst 8 744 812 kronor, varav högst 6 995 849,6 kronor avser de nya aktierna och högst 1 748 962,4 kronor avser de nya aktier som kan komma att tecknas genom utnyttjande av teckningsoptionerna. Aktiekapitalökningen är beräknad på ett kvotvärde om 0,10 kronor per aktie.

Rätt att teckna units

Units ska tecknas med företrädesrätt av Bolagets aktieägare. För varje aktie som innehas på avstämningsdagen erhåller aktieägaren en uniträtt, varvid en uniträtt berättigar till teckning av en unit. Avstämningsdag för bestämmande av vilka aktieägare som ska vara berättigade att med företrädesrätt teckna units ska vara den 16 juni 2023.

För det fall inte samtliga units tecknats med stöd av uniträtter ska styrelsen bestämma att tilldelning av units tecknade utan stöd av uniträtter ska äga rum inom ramen för emissionens högsta belopp, varvid styrelsen ska tilldela units i första hand till de som också tecknat units med stöd av uniträtter, och, vid överteckning, pro rata i förhållande till deras teckning med stöd av uniträtter. I andra hand ska styrelsen tilldela units till de som tecknat units utan stöd av uniträtter och, om full tilldelning inte kan ske, pro rata i förhållande till deras teckning. I den mån detta inte kan ske ska tilldelning ske genom lottning samt, i sista hand, under förutsättning att sådan tilldelning krävs för att emissionen ska bli fulltecknad, till garanterna av emissionen.

Teckningskurs för units

Teckningskursen är 1,60 kronor per unit, motsvarande 0,80 kronor per aktie. Teckningsoptionerna emitteras vederlagsfritt. Vid full teckning ger det en total teckningslikvid om cirka 56 miljoner kronor.

Överkurs ska tillföras den fria överkursfonden.

Teckning och betalning avseende units

Teckning av units med stöd av uniträtter ska ske genom kontant betalning under tiden från och med den 20 juni 2023 till och med den 7 juli 2023. Styrelsen ska äga rätt att förlänga teckningstiden.

Teckning av units utan stöd av uniträtter ska ske genom anmälan på särskild anmälningssedel under tiden från och med den 20 juni 2023 till och med den 7 juli 2023. Styrelsen ska äga rätt att förlänga teckningstiden. Betalning för tecknade units ska erläggas senast tredje bankdagen efter att avräkningsnota som utvisar besked om tilldelning avsänts till tecknaren, eller sådant senare datum som styrelsen bestämmer.

Handel med uniträtter beräknas ske under tiden från och med den 20 juni 2023 till och med den 4 juli 2023. Handel i BTU (Betalda Tecknade Units) beräknas ske från och med den 20 juni 2023 till och med runt vecka 30 2023.

Teckning och teckningskurs för nya aktier vid teckning med utnyttjande av teckningsoptioner

Teckning av nya aktier genom utnyttjande av teckningsoptioner ska kunna ske under tidsperioden från och med den 2 januari 2025 till och med den 31 januari 2025.

Två (2) teckningsoptioner berättigar innehavaren till teckning av en (1) ny aktie i bolaget till en teckningskurs per aktie (”Lösenpriset”) motsvarande det högre av (i) 70 procent av den volymvägda genomsnittliga betalkursen för bolagets aktie på Nasdaq First North Growth Market under en period om 10 handelsdagar omedelbart föregående teckningsperioden, dock högst 2 kronor per aktie, och (ii) aktiens kvotvärde vid tidpunkten för utnyttjande av teckningsoptioner. Den del av Lösenpriset som överstiger kvotvärdet för Bolagets aktier ska fördelas till den fria överkursfonden. Om det inte noteras någon betalkurs för viss handelsdag inom angiven tidsperiod ska sådan dag inte beaktas utan tidsperioden ska istället förlängas bakåt i tiden med det antal närmast föregående handelsdagar som krävs för att perioden ska omfatta totalt 10 handelsdagar med noterad betalkurs. Det således framräknade Lösenpriset ska avrundas till två decimaler varvid 0,5 öre ska avrundas uppåt.

Rätt till utdelning för nya aktier

De nya aktierna ska medföra rätt till vinstutdelning första gången på den avstäm­nings­dag för utdelning som infaller efter det att aktierna har registrerats hos Bolagsverket.

Övrigt

Styrelsen, eller den som styrelsen utser, ska ha rätt att vidta de smärre justeringar av ovanstående beslut som kan visa sig erforderliga i samband med registrering av beslutet vid Bolagsverket eller Euroclear Sweden AB.

Beslutet om företrädesemissionen förutsätter att bolagsordningen ändras enligt punkten 12 ovan.

Punkt 14 – Beslut om bemyndigande för styrelsen att besluta om nyemission

Styrelsen föreslår att årsstämman beslutar om bemyndigande för styrelsen att inom ramen för gällande bolagsordning, med eller utan avvikelse från aktieägarnas företrädesrätt, vid ett eller flera tillfällen under tiden fram till nästa årsstämma, fatta beslut om ökning av Bolagets aktiekapital genom nyemission av aktier i bolaget. Syftet med bemyndigandet och skälen till eventuell avvikelse från aktieägarnas företrädesrätt är att emissioner ska kunna ske för att öka Bolagets finansiella flexibilitet och styrelsens handlingsutrymme, kunna bredda aktieägarkretsen i Bolaget samt för att kunna finansiera eventuella företagsförvärv och förvärv av verksamheter eller rörelser som Bolaget kan komma att genomföra.

Det totala antalet aktier som omfattas av sådana nyemissioner i enlighet med detta bemyndigande ska inte begränsas på annat sätt än genom gränserna för aktiekapitalet och antalet aktier såsom angivet i Bolagets vid var tid registrerade bolagsordning. Emissionerna ska ske till marknadsmässig teckningskurs, med förbehåll för marknadsmässig emissionsrabatt i förekommande fall, och betalning ska kunna ske genom kontant betalning, apportegendom eller genom kvittning, eller eljest med villkor.

Styrelsen eller den styrelsen utser bemyndigas att vidta de smärre justeringar som krävs för beslutets registrering vid Bolagsverket. För beslut i enlighet med styrelsens förslag krävs att beslutet biträds av aktieägare med minst två tredjedelar av såväl de avgivna rösterna som de aktier som är företrädda vid stämman.

Uppgifter om antalet aktier och röster

Vid tidpunkten för denna kallelses utfärdande uppgår det totala antalet aktier och röster i Bolaget till 34 979 248 stycken.

Aktieägares rätt att erhålla upplysningar

Aktieägarna erinras om rätten att vid stämman begära upplysningar från styrelsen och verkställande direktören i enlighet med 7 kap. 32 § aktiebolagslagen (2005:551).

Tillhandahållande av handlingar

Bolagets årsredovisning och revisionsberättelse avseende räkenskapsåret 2022, styrelsens fullständiga förslag till beslut enligt ovan samt övriga handlingar enligt aktiebolagslagen kommer att hållas tillgängliga för aktieägarna på Bolagets huvudkontor; Kopparbergsvägen 10, 722 13 Västerås samt på Bolagets hemsida www.realheart.se senast från och med onsdagen 24 maj 2023.

Handlingarna skickas också till de aktieägare som begär det och som uppger sin postadress.

Västerås i maj 2023

Scandinavian Real Heart AB

STYRELSEN

Notice to Attend the Annual General Meeting in Scandinavian Real Heart AB

Press Release, 16 May 2023

The shareholders in Scandinavian Real Heart AB, reg. no. 556729–5588 (the "Company"), are hereby invited to the Annual General Meeting on Wednesday, 14 June 2023 at 15.00 at Best Western Plus Hotel Plaza, Kopparbergsvägen 10, 722 13 Västerås. Registration for the Meeting begins at 14:30.

Right to participate in the Meeting, etc.

Shareholders who wish to participate in the Meeting shall

  • be recorded in the share register kept by Euroclear Sweden AB no later than Monday, 5 June 2023, and
  • notify the Company their intention to participate no later than Thursday, 8 June 2023 by post to Scandinavian Real Heart AB, Kopparbergsvägen 10, 722 13 Västerås, by phone +46 (0)70-643 88 61 or by e-mail jonas.bark@realheart.se. The notification shall state full name, personal identification number/company registration number, shareholding, address, daytime telephone number and, if applicable, information about proxies or assistants (maximum two).

To be entitled to participate in the Meeting, shareholders whose shares are held in the name of a nominee must, in addition to providing notification of their participation in the Meeting, re-register the shares in their own name so that the shareholders are registered in the share register on the record date on Monday, 5 June 2023. This re-registration may be temporary (so-called “voting right registration”) and is carried out through the nominee according to their procedures at a time predetermined by the nominee. Voting rights registration that has been completed by the nominee no later than Thursday, 8 June 2023, are considered when preparing the share register.

Proxies etc.

If a Shareholders shall be represented by proxy, the proxy shall bring a written, dated and by the shareholder signed, power of attorney to the Meeting. The power of attorney may not be older than one year unless indicated that it is valid for a longer period, not exceeding five years. If the proxy is issued by a legal person, the proxy shall bring a current copy of the registration certificate and similar papers of authorisation. In order to facilitate entry to the Meeting, a copy of the power of attorney and other authorisation documents should be attached to the notification to the Meeting. Proxy forms will be available on the Company's website www.realheart.se and will be sent by post to shareholders who contact the Company and state their address.

Processing of personal data

For information on how personal data is processed in connection with the Meeting, please refer to the privacy policy available on Euroclear Sweden AB's website: https://www.euroclear.com/dam/ESw/Legal/Integritypolicy-bolagsstammor-svenska.pdf.

Proposal for agenda

  1. Election of Chairman of the Meeting
  2. Election of one or two persons to verify the minutes
  3. Preparation and approval of the voting list
  4. Approval of the agenda
  5. Determination as to whether the meeting has been duly convened
  6. Presentation of the annual report and the auditor’s report
  7. Resolution on
  1. adoption of the profit and loss statement and the balance sheet;
  2. appropriation of the Company’s profit or loss as set forth in the adopted balance sheet;
  3. discharge of the Board members and the CEO from liability
  1. Determination of number of Board members and auditors
  2. Determination of fees for Board members and auditor
  3. Election of Board members, Chairman of the Board and auditor
  4. Election of Nomination Committee
  5. Resolution on amendment of the Articles of Association
  6. Approval of the resolution by the Board of Directors to issue new units consisting of shares and warrants with preferential rights for the shareholders
  7. Resolution on authorisation for the Board of Directors to resolve on a new share issue
  8. Closing of meeting

The Nomination Committee’s proposals

The Nomination Committee's proposals regarding the election of Chairman of the Meeting (item 1), determination of number of Board members and auditors (item 8), determination of fees for Board members and auditor (item 9), election of Board members, Chairman of the Board and auditor (item 10) as well as the election of the Nomination Committee (item 11) will be presented on the Company's website www.realheart.se well in advance of the Meeting.

The Board of Directors’ proposals

Item 7 b – Resolution on appropriation of the Company’s profit or loss as set forth in the adopted balance sheet (item 8 b)

The Board of Directors proposes that the Annual General Meeting shall resolve that distributable profits are carried forward and not to distribute any dividends for the financial year 2022. 

Item 12 – Resolution on amendment of the Articles of Association

The Board of Directors proposes that the Meeting resolves to amend the Articles of Association in accordance with the following:     

Current wording: Proposed wording:
§ 4 Share Capital The share capital of the company shall amount to not less than SEK 2,000,000 and not more than SEK 8,000,000. § 4 Share Capital The share capital of the company shall amount to not less than SEK 7,000,000 and not more than SEK 28,000,000.
§ 5 Number of shares The number of shares in the company shall be not less than 20,000,000 and not more than 80,000,000 shares. § 5 Number of sharesThe number of shares in the company shall be not less than 70,000,000 and not more than 280,000,000 shares.

Furthermore, the Board of Directors proposes that the Meeting resolve to introduce a new section 11 in the Articles of Association which allows the General Meeting to be held in Västerås or Stockholm as set out below.

Proposed wording:
§ 11 Location for the general meetingA general meeting may be held in Västerås or Stockholm.

Since it is proposed that the section be inserted as a new section 11, it is also proposed to renumber subsequent sections in the Articles of Association so that previous sections 11–13 become sections 12–14.

The resolution shall be conditional on the Meeting approving the Board's resolution on a new issue of units with preferential rights for the shareholders in accordance with item 13 below.

The Board of Directors or a person appointed by the Board of Directors shall be authorised to make such minor adjustments to the resolution that may prove necessary for registration of the decision with the Swedish Companies Registration Office. For a valid resolution in accordance with the Board’s proposal, it is required that the resolution is supported by shareholders who represent at least two-thirds of both the votes cast and the shares represented at the Meeting

Item 13 – Approval of the resolution by the Board of Directors to issue new units consisting of shares and warrants with preferential rights for the shareholders

The Board of Directors proposes that the Meeting resolves to approve the Board of Directors’ resolution of 15 May 2023, on issuance of so called units, in the form of new shares and warrants giving right to subscribe for new shares, with preferential rights for the shareholders in accordance with below.

Number of units and share capital increase

The issue comprises no more than 69,958,496 new shares and no more than 34,979,248 warrants of series TO2, which may only be subscribed for and allotted together in the form of so called units where each unit consists of two (2) shares and one (1) warrant of series TO2. After the issue, the shares and the warrants will be separated. Two warrants entitles to subscription of one (1) new share in the Company.

The Company’s share capital may be increased through subscription of the new shares and through exercise of the warrants for subscription of new shares. The Company’s share capital may be increased by no more than SEK 8,744,812, out of which no more than SEK 6,995,849.6 is from the new shares and no more than SEK 1,748,962.4 is from the new shares that may be subscribed for through exercise of the warrants. The share capital increases have been calculated based on a quotient value of SEK 0.10 per share. 

Right to subscribe for units

The shareholders of the Company shall have preferential rights to subscribe for units. For each share held on the record date, the shareholder receives one unit right, whereby one unit right entitles to subscribe for one unit. The record date for determining which shareholders shall be entitled to subscribe for units on a preferential basis shall be 16 June 2023.

In case not all units have been subscribed for, the Board of Directors shall decide that allotment of units subscribed for without unit rights shall take place up to the maximum amount of the issue, whereby the Board of Directors primarily will allot units to those who also subscribed for units based on unit rights, and in the event of over subscription, pro rata to their subscription based on unit rights. Secondly, the Board of Directors will allot units to those who subscribed for units without unit rights, and if full allotment cannot be made, pro rata to their subscription. To the extent not possible, allotment shall be made through drawing of lots, and finally, subject to such allocation being required in order for the issue to be fully subscribed, to the guarantors of the issue.

Subscription price of units

The subscription price is SEK 1.60 per unit, corresponding to SEK 0.80 per share. The warrants are issued free of charge. In the case of full subscription, this provides issuing proceeds of approximately MSEK 56.

The share premium shall be transferred to the unrestricted premium reserve.

Subscription and payments of units

Subscription for units based on unit rights shall be made through payment in cash during the period from 20 June 2023 until, and including 7 July 2023. The Board of Directors shall be entitled to extend the subscription period.

Subscription without unit rights shall be made through notice on special application form during the period from 20 June 2023 until, and including 7 July 2023. The Board of Directors shall be entitled to extend the subscription period. Payment for units shall be made at the latest three business days following the date of the dispatch of a contract note to the subscriber, specifying allocation of units, or such later date as the Board of Directors may decide.

Trading with unit rights is expected to take place during the period from 20 June 2023 until, and including 4 July 2023. Trading in BTU (Paid Subscribed Units) is expected to take place from 20 June 2023 until, around week 30 2023. 

Subscription and subscription price of new shares subscribed for through exercise of warrants

Subscription of new shares through exercise of warrants may be made during the period from and including 2 January 2025 up to and including 31 January 2025.

Two (2) warrants entitle the holder to subscribe for one (1) new share in the Company at a subscription price per share (the “Exercise Price”) corresponding to the higher of (i) 70 percent of the volume weighted average trading price of the company’s share on Nasdaq First North Growth Market during a period of 10 trading days immediately preceding the subscription period, however no more than SEK 2 per share, and (ii) the quotient value of the share at the time of exercise of warrants. The part of the Exercise Price exceeding the quota value of the Company’s shares shall be allocated to the unrestricted share premium fund. If no trading price is recorded for a particular trading day within the specified period, such day shall not be taken into account, but the period shall instead be extended backwards in time with the number of previous trading days required for the period to comprise a total of 10 trading days with a recorded trading price. The Exercise Price calculated in accordance with above shall be rounded off to two decimals, where SEK 0.005 shall be rounded upwards.

Right to dividends of new shares

The new shares shall entitle to dividends as from the first record date for dividends following registration of the new shares with the Swedish Companies Registration Office.

Miscellaneous

The Board of Directors, or a person appointed by the Board of Directors, shall be authorised to make any minor adjustments required to register the resolution with the Swedish Companies Registration Office or Euroclear Sweden AB.

The resolution on a rights issue is conditional upon that the Articles of Association are amended according to item 12 above.

Item 14 – Resolution on authorisation for the Board of Directors to resolve on a new share issue

The Board of Directors proposes that the Annual General Meeting resolve on authorisation for the Board of Directors to, within the limits of the applicable Articles of Association, with or without deviating from the shareholders' preferential rights, on one or more occasions during the period until the next Annual General Meeting, resolve on an increase in the Company's share capital through a new issue of shares in the Company. The purpose of the authorisation and the reasons for any deviation from the shareholders' preferential rights is that new issues should be able to take place in order to increase the Company's financial flexibility and the Board's capacity for action, to be able to broaden the shareholder base in the Company and to be able to finance any business mergers and acquisitions of operations or businesses that the Company may carry out.

The total number of shares to be issued by in accordance with the authorisation shall not be limited in any other way than by the limits of the share capital and the number of shares included in the Company's Articles of Association registered at any time. The issues shall be carried out at a market-based subscription price, subject to a market-based issue discount where applicable, and payment shall be made through cash payment, with property in kind or by set-off, or with other conditions.

The Board of Directors or a person appointed by the Board of Directors shall authorised to make the minor adjustments required for the registration of the resolution at the Swedish Companies Registration Office. For a valid resolution in accordance with the Board's proposal, the resolution must be supported by shareholders with at least two-thirds of both the votes cast and the shares represented at the Meeting.

Information on the number of shares and votes

At the time of issue of this notice, the total number of shares and votes in the Company amounts to 34,979,248.

Shareholders’ right to request information

The shareholders are reminded of their right, in accordance with Chapter 7 Section 32 of the Swedish Companies Act (2005:551), to request information from the Board Directors and the CEO at the Meeting.

Provision of documents

The Company's annual report and audit report for the financial year 2022, the Board of Directors' complete proposals for resolutions as set out above as well as other documents according to the Swedish Companies Act will be kept available to the shareholders at the Company's head office; Kopparbergsvägen 10, 722 13 Västerås and on the Company's website www.realheart.se no later than Wednesday 24 May 2023. Copies of the documents will also be sent to shareholders who so request and who provide their postal address.

Västerås in May 2023

Scandinavian Real Heart AB

THE BOARD OF DIRECTORS

Interim Report 230101-230331

Press Release 11 May, 2023

Revenue and Result

Scandinavian Real Heart is working with research and development and currently has no sales of any products. The income reported for the period consists mainly of foreign currenty exhance gains. Research and development costs of Realheart® TAH were capitalized during the year with 4.1 MSEK. During the period, write-downs of capitalized costs for research and development were made by 0 MSEK.

The item other external costs of 4.2 MSEK consists of costs for purchased services of 1.0 MSEK and various other costs of 3.2 MSEK. Of these costs, 4.1 MSEK has been capitalized.

Financial Position

During the period, the company has received cash of 3.7 MSEK from an extended loan from ALMI and 4.1 MSEK from TO1. With a cash balance of 10.5 MSEK, the companty has funding that will last into third quarter of 2023.

In order to solve the Company's longer-term financing needs, Realheart works continuously to evaluate alternatives for further capitalization of the Company.

Significant Events During the First Quarter of the Year

January starts with communicating increased survival time from one to four days, and also that several performance criteria were increased. All this was reached in the end of 2022, but was communicated in 2023, after collection of data including analysis. The main citieria were: no hemolysis, no thromboembolic events, high pumping capacity and good right-left balance, and short procedure.

In January, the company also communicates that they, together with KTH, developed Sweden's First Patient Simulator. The collaboration between Realheart and KTH to develop the simulator (scientific term: "hybrid simulator") began in 2022 after a contribution of SEK 4 million from Smart Elektronik, a joint initiative by Vinnova, Formas and the Swedish Energy Agency.

In Januari, the company also communicates that Dr. Ulf Kjellman Strengthens Realheart's Medical Advisory Board. Ulf Kjellman has over 35 years of experience in cardiothoracic surgery.

End of February, Professor Bart Meyns Strengthens Realheart's Advisory Board. Dr Meyns is a Professor at the University of Leuven in Belgium and is also leading Realheart's surgical team in the ongoing animal study.

In the beginning of March, Realheart announces the outcome of the exercise of warrants of series TO1. A total of 7 183 148 warrants of series TO1 were exercised, corresponding to approximately 70 percent of the total number of warrants, which brings the Company approximately SEK 4.2 million before issuing related costs.

Last days of March, cardiac surgeon Ulf Kjellman Takes over as Chief Medical Officer (CMO) at Realheart. Kjellman, who has many years of experience in advanced cardiac surgery, will be clinically responsible for the company's preclinical and clinical studies.

The first quarter ends with Realheart's CEO to Present at the Swiss Nordic Bio Zürich Healthcare Investor Conference. There is an increased interest in the possibilities of total artificial hearts (TAH) and the interest in Realheart is much higher this year compared to last year's conference. Artificial hearts open the door to a paradigm shift in the care of patients with severe heart failure. Here, saving lives and reducing healthcare costs go hand in hand.

Significant Events After the end of the Period

In the middle of April the company communicates that the market need in the US and Europe is estimated at 200,000 artificial hearts per year – equivalent to SEK 200 Billion – and the trend is accelerating. Industry players and Realheart estimate that the market potential for total artificial hearts (TAHs) is over 200,000 units per year in Europe and the US. Realheart believes it is well positioned to take significant market share with its four-chamber artificial heart.

In April, Joseph Bornoff’s Simulations of the Realheart is Published in the Springer Nature Journal Scientific Reports. It is an advanced computational fluid dynamics (CFD) model of the Realheart® TAH (Total Artificial Heart) to study blood flow in the pump and optimize its function. The work has been co-authored with colleagues at Realheart.

At the end of April, results of Scandinavian Realheart’s Total Artificial Heart demonstrating lower rates of hemolysis are published. The peer-reviewed study titled ”In Vitro Hemolytic Performance of the Realheart V11C TAH Prototype with Porcine Blood” was published in the journal of Artificial Organs.

During the first days in May, scientists at Scandinavian Real Heart and at the University of Bath publish the world’s first computer simulation method for dual mechanical heart valves in series. The article “Overset meshing in combination with novel blended weak-strong fluid-structure interactions for simulations of a translating valve in series with a second valve” was published in the scientific journal “Computer

CEO Ina Laura Perkins has the Word

I am pleased to look back at a busy and very successful first quarter of 2023 with several key achievements for Realheart.

First, and foremost, by reaching the four-day survival benchmark of animals implanted with our TAH, we have shown that the Company is on track towards obtaining approval for the first in human use of our implant. This is the result of significant efforts by our R&D team, surgeons, and others who continue to improve surgical methodology and study protocols to a level where the procedure is becoming routine.

Similarly, our R&D team together with researchers at KTH Royal Institute of Technology, successfully developed the first patient simulator (digital twin) that is used to test the Company’s TAH algorithm. Apart from this being a “first” in our space, having access to digital twin technology will improve and streamline our R&D processes for current and future products. The project was rewarded with a grant from the Strategic Innovation Program Smarter Electronic Systems – a joint initiative by Vinnova, Formas and the Swedish Energy Agency.

We have continued to expand our team with two world renowned cardiac surgeons: Dr. Ulf Kjellman has been appointed as the Company’s CMO, and Prof. Bart Meyns has joined our Medical Advisory Board. Both are Key Opinion leaders with extensive experience in cardiac surgery and from the field of developing and testing heart pumps.

With the support of our shareholders, we have successfully raised 4.2 MSEK from warrants of series TO1. In an increasingly competitive and rapidly evolving environment, this as well as future financing, are critical for us to continue our current trajectory of successes, to effectively progress the development of the Realheart® TAH into the clinic towards product approval, and to create shareholder value.

We have continued to promote Realheart on the international stage to both investors and the medical and scientific community. Dr Azad Najar, our founder and Chief Innovation Officer, was selected as keynote speaker at the Artificial

Intelligence (AI) Conference in Cairo and the Dubai Innovation Conference.

And I have, together with Dr Oliver Voigt, presented Realhart at the Healthcare Investor Conference, Swiss Nordic Bio, in Zürich. Creating awareness and an international footprint of our technology among investors and the medical and scientific communities is key to the future success of the Company.

Significant events after the end of the period is that Realheart has published three scientific articles, in Springer Nature journal Scientific Reports, the journal Artificial Organs, and Computer Methods in Biomechanics and Biomedical Engineering . This is really important work, done in international collaboration between scientists at Realheart and researchers at the University of Bath and Swansea University Medical School, both in the United Kingdom.

After an eventful start of the year, we are incredibly excited and full of confidence. Knowing that we are on the right track, we are looking forward to completing our pre-clinical studies. Again, I want to highlight that support from current and future shareholders is essential for us to continue on our path to success.

Ina Laura Perkins

CEO, Scandinavian Real Heart AB

Scandinavian Real Heart AB

Swedish innovation power has given the world medical technology inventions such as the heart and lung machine, the pacemaker and the dialysis machine. The next big innovation is Realheart's artificial heart. A Swedish patented innovation that will save the lives of heart failure patients. Every year, 3,500 people die of heart failure in Sweden alone. Today, the only rescue is a heart transplant, but the number of donated hearts is only enough for 2% of those in need.

The start-up of the company was initiated by the doctor Azad Najar in 1999 when he started sketching an artificial heart that completely mimics the biological. In 2007, Azad co-founded Scandinavian Real Heart with two partners. The original idea behind Realheart® TAH is based on flow analyzes made at KTH 2002-2005 and is based on constructing an artificial heart that mimics the biological. By imitating its basic principle, a pressure and flow is created that reduces the risk of blood clots and provides an energy-efficient blood flow. These factors are important to give the patient a good quality of life. The development of the product has progressed strongly over the years. Blood circulation, pump function, pressure, and pulse generation have been verified in ethically approved animal experiments. Today, research and development takes place in close collaboration with world-leading heart surgeons, researchers and engineers.

Patent Protection

Realheart has granted patents in Sweden, Germany, the United Kingdom, the United States, China and India that protect the original pump principle in TAH. This patent also provides protection for future products: RealVAD® and PulsePump®.

Patent protection is also available on the latest version of Realheart® TAH in Sweden, USA, UK, Australia and Japan. The patent application for it has also been filed for Germany and Canada. The patents provide protection in the markets that are largest and most important for artificial hearts right now, with the exception of China and India which are considered important emerging markets. In addition to the patent protection described above, Realheart has also approved patents in Sweden, the USA and the United Kingdom for the future Sternal prosthesis product. The application is also submitted in Germany and France. In 2018, a new connection was designed for a simple and secure connection between Realheart® TAH and the body's circulatory system. The patent application for this has also been filed.

Finally, the patent application has been filed in two parts for the use of pressure sensors for the automatic control. Given the existing patents together with the new patent applications, the Board believes that the company has a strong patent situation and strong intellectual property protection.

Mission and Goal

Realheart's mission is to use medical technology solutions to save as many heart failure patients as possible and to create the best conditions for a life-affirming continuation of life. The company's overall goal is for the artificial heart to be commercialized and become a full-fledged treatment alternative for patients with heart failure. The heart should have a better function than the solutions that are on the market today. It should be possible to use both as a bridge to transplantation and as final therapy.

The Stock

Scandinavian Real Heart AB was listed on the Nasdaq First North Growth Market in December 2021. Nasdaq First North GM is a registered SME marketplace for growth companies that enables Nordic and international entrepreneurs to gain access to growth capital to develop and expand their operations. As of March 31, 2023, the number of shares in Scandinavian Real Heart was 34 979 248.

Principles for the preparation of the Interim Report

The interim report has been prepared in accordance with the Annual Accounts Act and with the application of general advice, recommendations and statements from the Swedish Accounting Standards Board.

Audit Review

The interim report has not been reviewed by the Company's auditor.

Upcoming Financial Reports

Annual Report 2022 2023-05-26

Interim Report Q2, 2023 2022-08-24

Interim Report Q3, 2023 2022-11-16

Year-end Report, 2023 2023-02-15

Annual General Meeting

The company's annual general meeting is planned to be held Friday, June 16th.

Submission of Interim Report

Västerås, May11, 2023

The Board

Scandinavian Real Heart AB

For Further Information, Please Contact

Ina Laura Perkins

CEO Scandinavian Real Heart

Phone: +46 70 406 49 21

E-mail: inalaura.perkins@realheart.se

Jonas Caspari Bark

CFO Scandinavian Real Heart

Phone: +46 70 643 88 61 E-mail: jonas.bark@realheart.se

This disclosure contains information that Real Heart is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information in this press release has been published through the agency of the contact persons set out below, at the time stated by Scandinavian Real Heart AB’s news distributor Cision upon publication of this press release.

Link to archive for financial reports: https://realheart.se/sv/investerare/arkiv/

Interim Report 230101-230331

Press Release 11 May, 2023

Revenue and Result

Scandinavian Real Heart is working with research and development and currently has no sales of any products. The income reported for the period consists mainly of foreign currenty exhance gains. Research and development costs of Realheart® TAH were capitalized during the year with 4.1 MSEK. During the period, write-downs of capitalized costs for research and development were made by 0 MSEK.

The item other external costs of 4.2 MSEK consists of costs for purchased services of 1.0 MSEK and various other costs of 3.2 MSEK. Of these costs, 4.1 MSEK has been capitalized.

Financial Position

During the period, the company has received cash of 3.7 MSEK from an extended loan from ALMI and 4.1 MSEK from TO1. With a cash balance of 10.5 MSEK, the companty has funding that will last into third quarter of 2023.

In order to solve the Company's longer-term financing needs, Realheart works continuously to evaluate alternatives for further capitalization of the Company.

Significant Events During the First Quarter of the Year

January starts with communicating increased survival time from one to four days, and also that several performance criteria were increased. All this was reached in the end of 2022, but was communicated in 2023, after collection of data including analysis. The main citieria were: no hemolysis, no thromboembolic events, high pumping capacity and good right-left balance, and short procedure.

In January, the company also communicates that they, together with KTH, developed Sweden's First Patient Simulator. The collaboration between Realheart and KTH to develop the simulator (scientific term: "hybrid simulator") began in 2022 after a contribution of SEK 4 million from Smart Elektronik, a joint initiative by Vinnova, Formas and the Swedish Energy Agency.

In Januari, the company also communicates that Dr. Ulf Kjellman Strengthens Realheart's Medical Advisory Board. Ulf Kjellman has over 35 years of experience in cardiothoracic surgery.

End of February, Professor Bart Meyns Strengthens Realheart's Advisory Board. Dr Meyns is a Professor at the University of Leuven in Belgium and is also leading Realheart's surgical team in the ongoing animal study.

In the beginning of March, Realheart announces the outcome of the exercise of warrants of series TO1. A total of 7 183 148 warrants of series TO1 were exercised, corresponding to approximately 70 percent of the total number of warrants, which brings the Company approximately SEK 4.2 million before issuing related costs.

Last days of March, cardiac surgeon Ulf Kjellman Takes over as Chief Medical Officer (CMO) at Realheart. Kjellman, who has many years of experience in advanced cardiac surgery, will be clinically responsible for the company's preclinical and clinical studies.

The first quarter ends with Realheart's CEO to Present at the Swiss Nordic Bio Zürich Healthcare Investor Conference. There is an increased interest in the possibilities of total artificial hearts (TAH) and the interest in Realheart is much higher this year compared to last year's conference. Artificial hearts open the door to a paradigm shift in the care of patients with severe heart failure. Here, saving lives and reducing healthcare costs go hand in hand.

Significant Events After the end of the Period

In the middle of April the company communicates that the market need in the US and Europe is estimated at 200,000 artificial hearts per year – equivalent to SEK 200 Billion – and the trend is accelerating. Industry players and Realheart estimate that the market potential for total artificial hearts (TAHs) is over 200,000 units per year in Europe and the US. Realheart believes it is well positioned to take significant market share with its four-chamber artificial heart.

In April, Joseph Bornoff’s Simulations of the Realheart is Published in the Springer Nature Journal Scientific Reports. It is an advanced computational fluid dynamics (CFD) model of the Realheart® TAH (Total Artificial Heart) to study blood flow in the pump and optimize its function. The work has been co-authored with colleagues at Realheart.

At the end of April, results of Scandinavian Realheart’s Total Artificial Heart demonstrating lower rates of hemolysis are published. The peer-reviewed study titled ”In Vitro Hemolytic Performance of the Realheart V11C TAH Prototype with Porcine Blood” was published in the journal of Artificial Organs.

During the first days in May, scientists at Scandinavian Real Heart and at the University of Bath publish the world’s first computer simulation method for dual mechanical heart valves in series. The article “Overset meshing in combination with novel blended weak-strong fluid-structure interactions for simulations of a translating valve in series with a second valve” was published in the scientific journal “Computer

CEO Ina Laura Perkins has the Word

I am pleased to look back at a busy and very successful first quarter of 2023 with several key achievements for Realheart.

First, and foremost, by reaching the four-day survival benchmark of animals implanted with our TAH, we have shown that the Company is on track towards obtaining approval for the first in human use of our implant. This is the result of significant efforts by our R&D team, surgeons, and others who continue to improve surgical methodology and study protocols to a level where the procedure is becoming routine.

Similarly, our R&D team together with researchers at KTH Royal Institute of Technology, successfully developed the first patient simulator (digital twin) that is used to test the Company’s TAH algorithm. Apart from this being a “first” in our space, having access to digital twin technology will improve and streamline our R&D processes for current and future products. The project was rewarded with a grant from the Strategic Innovation Program Smarter Electronic Systems – a joint initiative by Vinnova, Formas and the Swedish Energy Agency.

We have continued to expand our team with two world renowned cardiac surgeons: Dr. Ulf Kjellman has been appointed as the Company’s CMO, and Prof. Bart Meyns has joined our Medical Advisory Board. Both are Key Opinion leaders with extensive experience in cardiac surgery and from the field of developing and testing heart pumps.

With the support of our shareholders, we have successfully raised 4.2 MSEK from warrants of series TO1. In an increasingly competitive and rapidly evolving environment, this as well as future financing, are critical for us to continue our current trajectory of successes, to effectively progress the development of the Realheart® TAH into the clinic towards product approval, and to create shareholder value.

We have continued to promote Realheart on the international stage to both investors and the medical and scientific community. Dr Azad Najar, our founder and Chief Innovation Officer, was selected as keynote speaker at the Artificial

Intelligence (AI) Conference in Cairo and the Dubai Innovation Conference.

And I have, together with Dr Oliver Voigt, presented Realhart at the Healthcare Investor Conference, Swiss Nordic Bio, in Zürich. Creating awareness and an international footprint of our technology among investors and the medical and scientific communities is key to the future success of the Company.

Significant events after the end of the period is that Realheart has published three scientific articles, in Springer Nature journal Scientific Reports, the journal Artificial Organs, and Computer Methods in Biomechanics and Biomedical Engineering . This is really important work, done in international collaboration between scientists at Realheart and researchers at the University of Bath and Swansea University Medical School, both in the United Kingdom.

After an eventful start of the year, we are incredibly excited and full of confidence. Knowing that we are on the right track, we are looking forward to completing our pre-clinical studies. Again, I want to highlight that support from current and future shareholders is essential for us to continue on our path to success.

Ina Laura Perkins

CEO, Scandinavian Real Heart AB

Scandinavian Real Heart AB

Swedish innovation power has given the world medical technology inventions such as the heart and lung machine, the pacemaker and the dialysis machine. The next big innovation is Realheart's artificial heart. A Swedish patented innovation that will save the lives of heart failure patients. Every year, 3,500 people die of heart failure in Sweden alone. Today, the only rescue is a heart transplant, but the number of donated hearts is only enough for 2% of those in need.

The start-up of the company was initiated by the doctor Azad Najar in 1999 when he started sketching an artificial heart that completely mimics the biological. In 2007, Azad co-founded Scandinavian Real Heart with two partners. The original idea behind Realheart® TAH is based on flow analyzes made at KTH 2002-2005 and is based on constructing an artificial heart that mimics the biological. By imitating its basic principle, a pressure and flow is created that reduces the risk of blood clots and provides an energy-efficient blood flow. These factors are important to give the patient a good quality of life. The development of the product has progressed strongly over the years. Blood circulation, pump function, pressure, and pulse generation have been verified in ethically approved animal experiments. Today, research and development takes place in close collaboration with world-leading heart surgeons, researchers and engineers.

Patent Protection

Realheart has granted patents in Sweden, Germany, the United Kingdom, the United States, China and India that protect the original pump principle in TAH. This patent also provides protection for future products: RealVAD® and PulsePump®.

Patent protection is also available on the latest version of Realheart® TAH in Sweden, USA, UK, Australia and Japan. The patent application for it has also been filed for Germany and Canada. The patents provide protection in the markets that are largest and most important for artificial hearts right now, with the exception of China and India which are considered important emerging markets. In addition to the patent protection described above, Realheart has also approved patents in Sweden, the USA and the United Kingdom for the future Sternal prosthesis product. The application is also submitted in Germany and France. In 2018, a new connection was designed for a simple and secure connection between Realheart® TAH and the body's circulatory system. The patent application for this has also been filed.

Finally, the patent application has been filed in two parts for the use of pressure sensors for the automatic control. Given the existing patents together with the new patent applications, the Board believes that the company has a strong patent situation and strong intellectual property protection.

Mission and Goal

Realheart's mission is to use medical technology solutions to save as many heart failure patients as possible and to create the best conditions for a life-affirming continuation of life. The company's overall goal is for the artificial heart to be commercialized and become a full-fledged treatment alternative for patients with heart failure. The heart should have a better function than the solutions that are on the market today. It should be possible to use both as a bridge to transplantation and as final therapy.

The Stock

Scandinavian Real Heart AB was listed on the Nasdaq First North Growth Market in December 2021. Nasdaq First North GM is a registered SME marketplace for growth companies that enables Nordic and international entrepreneurs to gain access to growth capital to develop and expand their operations. As of March 31, 2023, the number of shares in Scandinavian Real Heart was 34 979 248.

Principles for the preparation of the Interim Report

The interim report has been prepared in accordance with the Annual Accounts Act and with the application of general advice, recommendations and statements from the Swedish Accounting Standards Board.

Audit Review

The interim report has not been reviewed by the Company's auditor.

Upcoming Financial Reports

Annual Report 2022 2023-05-26

Interim Report Q2, 2023 2022-08-24

Interim Report Q3, 2023 2022-11-16

Year-end Report, 2023 2023-02-15

Annual General Meeting

The company's annual general meeting is planned to be held Friday, June 16th.

Submission of Interim Report

Västerås, May11, 2023

The Board

Scandinavian Real Heart AB

For Further Information, Please Contact

Ina Laura Perkins

CEO Scandinavian Real Heart

Phone: +46 70 406 49 21

E-mail: inalaura.perkins@realheart.se

Jonas Caspari Bark

CFO Scandinavian Real Heart

Phone: +46 70 643 88 61 E-mail: jonas.bark@realheart.se

This disclosure contains information that Real Heart is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information in this press release has been published through the agency of the contact persons set out below, at the time stated by Scandinavian Real Heart AB’s news distributor Cision upon publication of this press release.

Link to archive for financial reports: https://realheart.se/sv/investerare/arkiv/

Realheart flyttar tidpunkt för Årsstämma samt publicering av Årsredovisning för 2022

Pressmeddelande 2023-04-19

Realhearts planerade årsstämma flyttas fram från den 26 maj till den 16 juni 2023. Anledningen till detta är att bolaget avser att arrangera en fysisk träff i Västerås och det tidigare kommunicerade datumet krockar med övriga planerade aktiviteter. I samband med detta flyttas även publiceringen av årsredovisningen för 2022 fram till 26 maj, det vill säga tre veckor innan tidpunkt för stämman, i enlighet med gällande regelverk.

Kallelse till årsstämman går i sedvanlig ordning ut fyra veckor före stämman, det vill säga den 19 maj.

Realheart Moves the Date of the Annual General Meeting and Publication of the Annual Report for 2022

Press Release 19 April, 2023

Realheart's planned Annual General Meeting (AGM) will be moved from May 26 to June 16, 2023. The reason for this is that the company intends to arrange a physical meeting in Västerås and the previously communicated date conflicts with other planned activities. In connection with this, the publication of the annual report for 2022 is also moved forward to May 26, i.e. three weeks before the date of the meeting, in accordance with current regulations.

Notice of the AGM will be sent out as usual four weeks before the meeting, i.e. on May 19.

Hjärtkirurgen Ulf Kjellman tar över som medicinsk chef (CMO) på Realheart

Pressmeddelande 2023-03-27

Hjärtkirurgen Ulf Kjellman, som nyligen tillträdde Realhearts medicinska råd, har nu tackat ja till att bli bolagets medicinska chef (Chief Medical Officer, CMO). Kjellman, som har mångårig erfarenhet av avancerad hjärtkirurgi, kommer att vara kliniskt ansvarig för bolagets prekliniska och kliniska studier.

– Jag känner en otrolig tillit till att Ulf Kjellman tillträder som medicinsk chef och därmed övertar det kliniska ansvaret. Jag kommer att fortsätta som innovationschef med utrymme att fokusera ännu mer på den fortsatta utvecklingen av Realhearts hela planerade produktlinje, närmast en mindre variant av Realheart som passar för kvinnor och mindre patienter, säger bolagets grundare Azad Najar.

Ulf Kjellman har över 35 års erfarenhet av hjärt- och thoraxkirurgi. På meritlistan finns bland annat ett djupt engagemang i att initiera och utveckla program för hjärttransplantation och hjärtpumpsbehandlingar vid flera sjukhus, både i Sverige och i andra länder, senast vid National Guard Hospital Riyadh i Saudiarabien.

– För mig var det ett enkelt beslut att tillträda rollen som kliniskt ansvarig på Realheart. Realhearts TAH är ett oerhört intressant koncept och ett paradigmskifte inom konstgjorda hjärtan. Som produkt fyller det ett tomrum inom vård av hjärtsviktspatienter, med potential att i framtiden rädda liv och ge patienterna en fortsatt bra livskvalitet, säger Ulf Kjellman.

Kjellman var en av de första att implantera både HeartMate 2 och HeartMate 3, efter CE-märkning (vänsterkammarassister utvecklade av Abbott). Han var även den hjärtkirurg som utförde den första implantationen av SynCardias konstgjorda hjärta i Sverige och Skandinavien 2008. Kjellman har publicerat flera vetenskapliga artiklar om hjärt- och kärlsjukdomar generellt och om hjärtpumpar specifikt. Ulf Kjellman har tack vare sin yrkeserfarenhet ett stort kontaktnät bland potentiella kunder, leverantörer och samarbetspartners, både i Sverige, Europa och Mellanöstern.

– Vi är oerhört glada och stolta över att Ulf Kjellman väljer att gå in i rollen som medicinsk chef. Även om hans expertis har funnits för oss sedan en tid tillbaka, så blir det från och med nu ännu tydligare vilken viktig roll han kommer att spela i vår fortsatta utveckling. Dr Kjellman blir ett mycket värdefullt tillskott i ledningsgruppen, där han bidrar med stor erfarenhet av hjärtkirurgi och transplantationer. Detta får i sin tur stor betydelse för våra framtida kliniska prövningar då patienterna kommer att få Realheart® TAH säger Ina Laura Perkins, vd på Realheart.

Cardiac Surgeon Ulf Kjellman Takes Over as Chief Medical Officer(CMO) at Realheart

Press Release 27 March, 2023

Cardiac surgeon Ulf Kjellman, who recently joined Realheart's medical advisory board, has now agreed to become the company's Chief Medical Officer (CMO). Kjellman, who has many years of experience in advanced cardiac surgery, will be clinically responsible for the company's preclinical and clinical studies.

"I feel incredibly confident that Ulf Kjellman takes over as medical director and thus assumes clinical responsibility. I will continue as head of innovation with room to focus even more on the continued development of Realheart's entire planned product line, mainly a smaller version of Realheart suitable for women and smaller patients," said company founder Azad Najar.

Ulf Kjellman has over 35 years of experience in cardiac and thoracic surgery. His experience includes a deep involvement in initiating and developing programs for heart transplantation and heart pump treatments at several hospitals, both in Sweden and in other countries, most recently at the National Guard Hospital Riyadh in Saudi Arabia.

“It was an easy decision for me to take on the role as Chief Medical Officer at Realheart. Realheart's TAH is an extremely interesting concept and a paradigm shift in artificial hearts. As a product, it fills a gap in the care of heart failure patients with the potential to save tens of thousands of lives within a decade," said Ulf Kjellman.

Kjellman was one of the first to implant both HeartMate 2 and HeartMate 3, after CE marking. (left ventricular assist devices developed by Abbott). He was also the cardiac surgeon who performed the first implantation of the SynCardia artificial heart in Sweden and Scandinavia in 2008. Kjellman has published several scientific articles on cardiovascular diseases in general and on heart pumps specifically. Thanks to his professional experience, Ulf Kjellman has a large network of contacts among potential customers, suppliers, and partners in Sweden, Europe, and the Middle East.

“We are extremely happy and proud that Ulf Kjellman chooses to step into the role of Chief Medical Officer. Although his expertise has been available to us for some time, it is now even clearer what an important role he will play in our continued development. Dr Kjellman will be a very valuable addition to the management team, where he brings extensive experience in cardiac surgery and transplantation. This in turn will be of great importance for our future clinical trials when patients will receive Realheart® TAH," said Ina Laura Perkins, CEO of Realheart.

Utfall av nyttjande av teckningsoptioner av serie TO1 i Scandinavian Real Heart AB

Pressmeddelande 2023-03-03

Scandinavian Real Heart AB (”Realheart” eller ''Bolaget'') meddelar idag utfallet av nyttjandet av teckningsoptioner av serie TO1. Totalt nyttjades 7 183 148 teckningsoptioner av serie TO1, motsvarande cirka 70 procent av det totala antalet optioner, vilket tillför Bolaget ca 4,2 MSEK före emissionskostnader.

Teckningsperioden löpte mellan den 1 – 28 februari 2023 och teckningsoptionerna emitterades i samband med Bolagets emission av units under tredje kvartalet 2021. Fyra (4) teckningsoptioner berättigade till teckning av en (1) ny aktie.

Totalt tecknades 1 795 787 aktier till den fastställda teckningskursen om 2,36 SEK. Nyttjandet av teckningsoptionerna medför att antalet aktier ökar från 33 183 461 till 34 979 248. För befintliga aktieägare uppgår utspädningen från nyttjandet av teckningsoptionerna till cirka 5,1 procent.

Så snart emissionen blivit registrerad hos Bolagsverket och Euroclear, vilket beräknas ske i mitten av mars 2023, omvandlas interimsaktier (IA) till ordinarie aktier och upptas till handel på Nasdaq First North Growth Market.

Finansiell rådgivare och emissionsinstitut

Skills Corporate Finance Nordic AB är finansiell rådgivare och Nordic Issuing AB är emissionsinstitut till Realheart i samband med utnyttjandet av teckningsoptioner av serie TO1.

Use of Warrants of Series TO1 in Scandinavian Real Heart AB

Press Release 3 March, 2023

Scandinavian Real Heart AB ("Realheart" or ''the Company'') today announces the outcome of the exercise of warrants of series TO1. A total of 7 183 148 warrants of series TO1 were exercised, corresponding to approximately 70 percent of the total number of warrants, which brings the Company approximately SEK 4.2 million before issuing related costs.

The subscription period ran from 1 – 28 February 2023 and the warrants were issued in connection with the Company's issuance of units in the third quarter of 2021. Four (4) warrants entitled the holder to subscribe for one (1) new share.

A total of 1,795,787 shares were subscribed for at the fixed subscription price of SEK 2.36. The exercise of the warrants increases the number of shares from 33 183 461 to 34 979 248. For existing shareholders, the dilution from the exercise of the warrants amounts to approximately 5.1 percent.

As soon as the issue has been registered with the Swedish Companies Registration Office and Euroclear, which is expected to take place in mid-March 2023, interim shares (IS) will be converted into ordinary shares and admitted to trading on the Nasdaq First North Growth Market.

Financial Advisor and Issuing Agent

Skills Corporate Finance Nordic AB is the financial advisor and Nordic Issuing AB is the issuing agent to Realheart in connection with the exercise of warrants of series TO1.

Rättelse: Delårsrapport 220701-220930

Pressmeddelande 2022-12-07

Företaget har i november 2022 upptäckt en felaktig redovisning av bidrag i Q3-rapporten i och med att erhållna offentliga stöd redovisas som övrig rörelseintäkt. Villkoren för de offentliga stöden innebär att stöden ska finansiera företagets utvecklingsprojekt och redovisas som förskott offentliga stöd på balansräkningen. 
Rättningen påverkar inte företagets kassaflöde utan är en flytt från resultaträkning till balansräkning.

Påverkan på moderbolaget och koncernen för Q3, 2022 blir enligt följande:

Correction: Interim Report 220701-220930

Press Release 7 December, 2022

In November 2022, the company discovered a misstatement of grants in the Q3 report, as the government grants received are reported as other operating income. The terms of the government grants require the grants to fund the company's development projects and are recorded as advance government grants on the balance sheet. The net amount does not affect the cash flow of the enterprise but is a transfer from the income statement to the balance sheet.

The impact on the Parent Company and the Group for Q3, 2022 will be as follows:

Jonas Caspari Bark New CFO at Realheart

Press release 27 June, 2022

Realheart has recruited Jonas Caspari Bark as its new Chief Financial Officer. He joins Realheart from a similar position with Ecokraft Sverige AB and has previously, among other things, worked in various roles within the ABB group. Jonas Caspari Bark starts on August 5.

Realheart is a Swedish company, headquartered in Västerås, that is developing the world's first artificial four-chamber heart. The company has recently taken several important steps forward, not least in leaving the prototype behind and now testing the clinical version of the heart in animal studies, with clinical trials expected to begin in 2024. As a result of this, interest in the company is increasing, and with it the need to further strengthen the finance function.

''I am so pleased to have been able to add Jonas Caspari Bark to our team when our current CFO Andreas Hultdin cannot be available to the extent we need going forward. He has been extremely important to Realheart and it is thanks to his skill and commitment that Jonas can now take over a finance function with well-structured and secure procedures and develop it further'' said Ina Laura Perkins, CEO.

Andreas Hultdin will leave his role on 5 August when Jonas Caspari Bark takes over, but Andreas will remain as a consultant to support the company as needed.

''Realheart's artificial heart is a super exciting product that will help save a lot of lives in the future. I am really looking forward to being involved in the work towards commercialisation. I have previous experience of getting onboard at this phase of the development process and hope to be able to contribute to our success, says Jonas Caspari Bark.

Jonas Caspari Bark ny CFO på Realheart

Pressmeddelande 2022-06-27

Realheart har rekryterat Jonas Caspari Bark som ny Chief Financial Officer. Han kommer närmast från Ecokraft Sverige AB och har tidigare bland annat arbetat i olika roller inom ABB. Jonas Caspari Bark börjar den 5 augusti och efterträder nuvarande CFO Andreas Hultdin.

Realheart är ett svenskt bolag med huvudkontor i Västerås, som utvecklar världens första artificiella fyrakammarhjärta. Bolaget har på senare tid tagit flera viktiga steg framåt, inte minst i det att man lämnat prototypen bakom sig och nu testar den kliniska versionen av Realheart® TAH i djurstudier. 2024 räknar man med att inleda kliniska studier. I samband med detta ökar intresset för bolaget, och med behovet av att ytterligare stärka ekonomifunktionen.

– Jag är så glad att jag har kunnat knyta Jonas Caspari Bark till vårt team när vår nuvarande CFO Andreas Hultdin inte kan vara tillgänglig i den utsträckning vi behöver framåt. Han har varit oerhört viktig för Realheart och det är tack vare hans skicklighet och engagemang som Jonas nu kan ta över en ekonomifunktion med välstrukturerade och trygga rutiner och utveckla den vidare, säger Ina Laura Perkins, vd på Realheart.

Andreas Hultdin slutar den 5 augusti då Jonas Caspari Bark tillträder, men kommer att finnas kvar som konsult och stötta bolaget vid behov.

– Realhearts artificiella hjärta är verkligen en superspännande produkt som i framtiden kommer att kunna rädda oerhört många liv. Jag ser verkligen fram emot vara med den sista biten till en kommersiell produkt. Jag har tidigare erfarenheter av att komma in i den här fasen av utvecklingen och hoppas kunna bidra till vår framgång, säger Jonas Caspari Bark.